Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 12/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23304935 | 0.87 | OGA (0.59) | OGA | |
| SCHEMBL23317296 | 0.86 | OGA (0.39) | OGALMNA | |
| SCHEMBL23317297 | 0.83 | OGA (0.40) | OGADRD2SMN1; SMN2 | |
| SCHEMBL23305245 | 0.76 | OGA (0.53) | OGA | |
| SCHEMBL23317387 | 0.75 | SIGMAR1 (0.46) | SIGMAR1OGA | |
| SCHEMBL11257702 | 0.75 | SIGMAR1 (0.71) | SIGMAR1DRD2HTR2A | |
| SCHEMBL23304989 | 0.75 | OGA (0.54) | OGACCR1 | |
| SCHEMBL29914275 | 0.75 | OGA (0.54) | OGACCR1 | |
| SCHEMBL2633399 | 0.74 | SIGMAR1 (0.51) | SIGMAR1DRD2HTR2AADRA1DADRA1A | |
| SCHEMBL23305438 | 0.74 | OGA (0.55) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021086966-A1 | SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |